Page last updated: 2024-11-01
nortriptyline and Gastric Stasis
nortriptyline has been researched along with Gastric Stasis in 1 studies
Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.
nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.
Research Excerpts
Excerpt | Relevance | Reference |
"To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis." | 9.17 | Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013) |
"To determine whether treatment with nortriptyline results in symptomatic improvement in patients with idiopathic gastroparesis." | 5.17 | Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. ( Abell, TL; Farrugia, G; Hamilton, F; Hasler, WL; Koch, KL; Lee, L; McCallum, RW; Nguyen, L; Parkman, HP; Pasricha, PJ; Sarosiek, I; Snape, WJ; Tonascia, J; Unalp-Arida, A; Van Natta, ML, 2013) |
Research
Studies (1)
Timeframe | Studies, this research(%) | All Research% |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
Parkman, HP | 1 |
Van Natta, ML | 1 |
Abell, TL | 1 |
McCallum, RW | 1 |
Sarosiek, I | 1 |
Nguyen, L | 1 |
Snape, WJ | 1 |
Koch, KL | 1 |
Hasler, WL | 1 |
Farrugia, G | 1 |
Lee, L | 1 |
Unalp-Arida, A | 1 |
Tonascia, J | 1 |
Hamilton, F | 1 |
Pasricha, PJ | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status |
Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)[NCT00765895] | Phase 3 | 130 participants (Actual) | Interventional | 2009-01-31 | Completed |
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Decrease From the Baseline GCSI of at Least 50% on Any Two Consecutive Follow-up Visits
A decrease from the baseline Gastroparesis Cardinal Symptom Index (GCSI) score (sum of the 9 individual symptom scores) of at least 50% on any two consecutive follow-up visits during the 15 week treatment period with maximum tolerated study drug dose. The total score ranges from 0-45 with higher scores indicating greater symptom severity. (NCT00765895)
Timeframe: at end of treatment, 15 weeks from baseline assessment
Intervention | participants (Number) |
---|
Nortriptyline | 15 |
Placebo | 14 |
Trials
1 trial available for nortriptyline and Gastric Stasis